World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
A J&J Copycat Could Extend Old Drug's Life - WSJ.com
Keywords:
Copies with slight changes to extend drug life with new brand names- Clarinex for Claritin, Nexium for Prilosec, Paliperidone for Risperdal being the latest in this new marketing strategy of drug companies to extend the life and sales of a successful drug. The drug companies try to market the copy drug as a significant improvement, which is what J&J is doing with Paliperidone. Experts are skeptical. Pricing of the generic versions of Risperdal or its copy will be much less expensive. Cost is a sensitive issue. About 15% of Risperdal's $1.35 billion sales were from Medicaid, generic substitutions offer potentially large savings. Meantime J&J did not do clinical tests between Risperdal and Paliperidone, the tests with 1600 patients compared Risperdal with a sugar pill. A psychiatry Professor at Duke and another professor at NYU are skeptical of J&J claims for Paliperidone. United Health shows savings of $150 million by using generics instead of Nexium, so managed care payors will tread carefully.
Paying for universal health coverage in the U.S.
04/18/2006
The Obama administration estimates it will cost about $120 billion to cover roughly 50 million uninsured. Everything from taxing high calorie sodas, limiting tax dedcuctions for charitable giving, or decuctions for employer provided health insurance, are all being looked at Some like limiting deductions on chartable giving lack support in Congress.
Grouped Articles
Health Battle Over Soda Flares in Mexico
Wall Street Journal 08/28/2013
Recession Swells Number of Uninsured to 50.7 Million
Wall Street Journal 09/17/2010
Exchanges See Little Progress on Uninsured
Wall Street Journal 01/20/2014
Wal-Mart Cuts Prices for Many Generic Drugs to $4 - WSJ.com
Wall Street Journal 09/22/2006
A J&J Copycat Could Extend Old Drug's Life - WSJ.com
Wall Street Journal 09/29/2006
As Patients, Doctors Feel Pinch, Insurer's CEO Makes a Billion - WSJ.com
Wall Street Journal 04/18/2006
Reinventing drugs, another method to boost sales used by pharmaceutical companies.
09/29/2006
By combining drugs that have lost protection with some other ingredient to make product extensions, companies like Glaxo have generated continued sales growth. Glaxo does this with Treximet for migraines.
Grouped Articles
A J&J Copycat Could Extend Old Drug's Life - WSJ.com
Wall Street Journal 09/29/2006
Glaxo Becomes Master of Reinventing Drugs
Wall Street Journal 04/17/2008
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Glaxo Tries to Shake Marketing Questions on Advair
Wall Street Journal 07/06/2012
Anemia drug made billions, but at what cost? - The Washington Post
Washington Post 07/20/2012
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us
